Vici, P <br/><br/>
A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  May 2012 
 - 1121-1129 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdr412  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Algorithms<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Breast Neoplasms--drug therapy<br/>Carcinoma--drug therapy<br/>Cyclophosphamide--administration & dosage<br/>Disease-Free Survival<br/>Docetaxel<br/>Dose-Response Relationship, Drug<br/>Epirubicin--administration & dosage<br/>Female<br/>Humans<br/>Italy<br/>Lymph Nodes--pathology<br/>Lymphatic Metastasis<br/>Middle Aged<br/>Prospective Studies<br/>Survival Analysis<br/>Taxoids--administration & dosage